非小细胞肺癌新辅助治疗疗效病理评估专家共识

2021-09-08 国家肿瘤质控中心肺癌质控专家委员会中华病理学杂志, 2021，50(09)

随着非小细胞肺癌新辅助治疗的进展，与疗效和预后密切相关的病理反应评估得到广泛应用，但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上，结合专家组临床实践数据及经验，并经反复讨论，由病理医

中文标题：

发布机构：

国家肿瘤质控中心肺癌质控专家委员会

发布日期：

2021-09-08

简要介绍：

随着非小细胞肺癌新辅助治疗的进展，与疗效和预后密切相关的病理反应评估得到广泛应用，但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上，结合专家组临床实践数据及经验，并经反复讨论，由病理医师与临床医师共同制定，涵盖了临床所需提供的关于新辅助治疗标本的临床信息、标本的规范化取材、病理反应评估、病理分期及病理诊断报告等内容，旨在进一步提高新辅助治疗病理学评估的准确性和一致性，为临床进一步治疗和预后预测提供可靠依据。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=043611c0021950e6, title=非小细胞肺癌新辅助治疗疗效病理评估专家共识, enTitle=, guiderFrom=中华病理学杂志, 2021，50(09), authorId=0, author=, summary=随着非小细胞肺癌新辅助治疗的进展，与疗效和预后密切相关的病理反应评估得到广泛应用，但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上，结合专家组临床实践数据及经验，并经反复讨论，由病理医, cover=https://img.medsci.cn/2021928/1632844628977_2020535.jpg, journalId=0, articlesId=null, associationId=1990, associationName=国家肿瘤质控中心肺癌质控专家委员会, associationIntro=国家肿瘤质控中心肺癌质控专家委员会, copyright=0, guiderPublishedTime=Wed Sep 08 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="article_abstract" style="color: #2c3e50;" data-v-da075436=""><span data-v-da075436="">随着非小细胞肺癌新辅助治疗的进展，与疗效和预后密切相关的病理反应评估得到广泛应用，但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上，结合专家组临床实践数据及经验，并经反复讨论，由病理医师与临床医师共同制定，涵盖了临床所需提供的关于新辅助治疗标本的临床信息、标本的规范化取材、病理反应评估、病理分期及病理诊断报告等内容，旨在进一步提高新辅助治疗病理学评估的准确性和一致性，为临床进一步治疗和预后预测提供可靠依据。</span></div>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4343, appHits=211, showAppHits=0, pcHits=1574, showPcHits=4128, likes=2, shares=11, comments=15, approvalStatus=1, publishedTime=Wed Sep 29 00:47:26 CST 2021, publishedTimeString=2021-09-08, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=qiushida2, createdTime=Tue Sep 28 23:57:19 CST 2021, updatedBy=6459136, updatedName=艺玮, updatedTime=Thu Jan 04 23:27:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=非小细胞肺癌新辅助治疗疗效病理评估专家共识.pdf)])

非小细胞肺癌新辅助治疗疗效病理评估专家共识.pdf

下载请点击：

评论区 (13)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2210624, encodeId=ae9b2210624ce, content=怎么的积分啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=216f2208037, createdName=120cc3bfm52暂无昵称, createdTime=Wed Jun 19 10:53:37 CST 2024, time=2024-06-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
2024-06-19 120cc3bfm52暂无昵称来自山东省

怎么的积分啊

26 1

展开1条回复
[GetPortalCommentsPageByObjectIdResponse(id=2210624, encodeId=ae9b2210624ce, content=怎么的积分啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=216f2208037, createdName=120cc3bfm52暂无昵称, createdTime=Wed Jun 19 10:53:37 CST 2024, time=2024-06-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
2023-12-11 ms3000000197638389 来自江苏省

如何下载

47 1

展开1条回复
[GetPortalCommentsPageByObjectIdResponse(id=2210624, encodeId=ae9b2210624ce, content=怎么的积分啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=216f2208037, createdName=120cc3bfm52暂无昵称, createdTime=Wed Jun 19 10:53:37 CST 2024, time=2024-06-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
2022-01-15 9700

谢谢

73 0
[GetPortalCommentsPageByObjectIdResponse(id=2210624, encodeId=ae9b2210624ce, content=怎么的积分啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=216f2208037, createdName=120cc3bfm52暂无昵称, createdTime=Wed Jun 19 10:53:37 CST 2024, time=2024-06-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
2022-01-08 ms4000000949064447

谢谢

74 0
[GetPortalCommentsPageByObjectIdResponse(id=2210624, encodeId=ae9b2210624ce, content=怎么的积分啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=216f2208037, createdName=120cc3bfm52暂无昵称, createdTime=Wed Jun 19 10:53:37 CST 2024, time=2024-06-19, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
2022-01-07 zZ大壮哥

学习学习

112 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

非小细胞肺癌新辅助治疗疗效病理评估专家共识

相关指南

拓展阅读

科室

工具

服务